MSKCC IDH Resist to EVA
Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations
We are uploading data from our targeted panel used in the publication referenced here, at the reuqest of the reviewers from Nature Medicine. The variant data included is from patients treated with IDH2 inhibitor Enasidanib who exhibited primary or acquired resistance to the investigational agent.
We are uploading data from our targeted panel used in the publication referenced here, at the reuqest of the reviewers from Nature Medicine. The variant data included is from patients treated with IDH2 inhibitor Enasidanib who exhibited primary or acquired resistance to the investigational agent.